Our Programs

CU-00048

• Next-generation T-type calcium channel modulator
• Lead indication: Essential Tremor
• Designed to build on the clinical validation of T-type modulation in Essential Tremor
• Differentiated state-dependent pharmacology
• Oral, brain-penetrant small molecule
• Preclinical efficacy in tremor-relevant models
• Favorable drug-like properties supporting potential once-daily dosing
• Translational Phase 1 strategy includes CNS target engagement using NREM EEG sigma-power
• Composition-of-matter intellectual property

Praxis Precision Medicines has made a major contribution by clinically validating T-type calcium channel modulation in Essential Tremor. Acurex is focused on the next-generation opportunity: a differentiated T-type modulator designed to preserve the benefits of the mechanism while improving tolerability, dose flexibility, and long-term treatment experience. 

CU-00213/ Selective CaV3.2 Program

• Selective Ca_V3.2 T-type calcium channel program
• Franchise expansion beyond CU-00048
• Designed for indications where Ca_V3.2-driven hyperexcitability, pain signaling, neuroinflammation, or neuronal vulnerability may contribute to disease
• Potential applications include pain, ALS, Parkinson’s disease, FTD-tau, and other neurological indications
• Lead optimization stage

CU-13001/ 15-LO Program

• 15-lipoxygenase inhibitor program
• Focused on neuroinflammation and neurodegeneration
• Targets upstream biology involved in lipid peroxidation, ferroptosis, oxidative stress, and neuronal vulnerability
• Potential applications include Parkinson’s disease, LRRK2-associated Parkinson’s disease, idiopathic Parkinson’s disease, ALS, Friedreich’s ataxia, and related neurodegenerative diseases
• Supported by external scientific validation, including an ASAP/MJFF-supported collaboration with leading Parkinson’s researchers
• Strategically positioned as a follow-on neuroinflammation and neurodegeneration program after the T-type Essential Tremor franchise

Acurex’s 15-LO program is designed to address upstream neurodegenerative biology that may be relevant across multiple disorders. Recent clinical results in Parkinson’s disease have prompted many in the field to look beyond direct LRRK2 kinase inhibition alone and to explore upstream mechanisms that may better protect vulnerable neurons before they are lost.